Literature DB >> 14525957

Structural determinants for vitamin D receptor response to endocrine and xenobiotic signals.

Ryutaro Adachi1, Andrew I Shulman, Keiko Yamamoto, Iichiro Shimomura, Sachiko Yamada, David J Mangelsdorf, Makoto Makishima.   

Abstract

The vitamin D receptor (VDR), initially identified as a nuclear receptor for 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3], regulates calcium metabolism, cellular proliferation and differentiation, immune responses, and other physiological processes. Recently, secondary bile acids such as lithocholic acid (LCA) were identified as endogenous VDR agonists. To identify structural determinants required for VDR activation by 1alpha,25(OH)2D3 and LCA, we generated VDR mutants predicted to modulate ligand response based on sequence homology to pregnane X receptor, another bile acid-responsive nuclear receptor. In both vitamin D response element activation and mammalian two-hybrid assays, we found that VDR-S278V is activated by 1alpha,25(OH)2D3 but not by LCA, whereas VDR-S237M can respond to LCA but not to 1alpha,25(OH)2D3. Competitive ligand binding analysis reveals that LCA, but not 1alpha,25(OH)2D3, effectively binds to VDR-S237M and both 1alpha,25(OH)2D3 and LCA bind to VDR-S278V. We propose a docking model for LCA binding to VDR that is supported by mutagenesis data. Comparative analysis of the VDR-LCA and VDR-1alpha,25(OH)2D3 structure-activity relationships should be useful in the development of bile acid-derived synthetic VDR ligands that selectively target VDR function in cancer and immune disorders without inducing adverse hypercalcemic effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14525957     DOI: 10.1210/me.2003-0244

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  18 in total

1.  Regulation of C/EBPbeta isoforms by MAPK pathways in HL60 cells induced to differentiate by 1,25-dihydroxyvitamin D3.

Authors:  Ewa Marcinkowska; Edward Garay; Elzbieta Gocek; Agnieszka Chrobak; Xuening Wang; George P Studzinski
Journal:  Exp Cell Res       Date:  2006-04-19       Impact factor: 3.905

Review 2.  Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds.

Authors:  E J Reschly; Matthew D Krasowski
Journal:  Curr Drug Metab       Date:  2006-05       Impact factor: 3.731

Review 3.  Bile acids regulate cardiovascular function.

Authors:  Sandeep Khurana; Jean-Pierre Raufman; Thomas L Pallone
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

4.  Bile Acid Receptors and Gastrointestinal Functions.

Authors:  Alexander L Ticho; Pooja Malhotra; Pradeep K Dudeja; Ravinder K Gill; Waddah A Alrefai
Journal:  Liver Res       Date:  2019-01-14

5.  Bile Acids in Hepatic Encephalopathy.

Authors:  Sharon DeMorrow
Journal:  J Clin Exp Hepatol       Date:  2018-05-04

Review 6.  The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis.

Authors:  Jiezhong Chen; Kong-Nan Zhao; Chen Chen
Journal:  Ann Transl Med       Date:  2014-01

7.  Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR.

Authors:  Matthew D Krasowski; Ai Ni; Lee R Hagey; Sean Ekins
Journal:  Mol Cell Endocrinol       Date:  2010-07-06       Impact factor: 4.102

Review 8.  Effects of bile acids on neurological function and disease.

Authors:  Matthew McMillin; Sharon DeMorrow
Journal:  FASEB J       Date:  2016-07-28       Impact factor: 5.191

Review 9.  Bile salts of vertebrates: structural variation and possible evolutionary significance.

Authors:  Alan F Hofmann; Lee R Hagey; Matthew D Krasowski
Journal:  J Lipid Res       Date:  2009-07-28       Impact factor: 5.922

10.  Evolution of the bile salt nuclear receptor FXR in vertebrates.

Authors:  Erica J Reschly; Ni Ai; Sean Ekins; William J Welsh; Lee R Hagey; Alan F Hofmann; Matthew D Krasowski
Journal:  J Lipid Res       Date:  2008-03-24       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.